Evidence map›Paper›PMID 28396686›Full record

ArticleInternational journal of endocrinology2017

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues.

Wenjuan Liu, Lina Xie, Min He, Ming Shen, Jingjing Zhu, Yeping Yang, Meng Wang, Ji Hu, Hongying Ye, Yiming Li and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Adenoma receptors and histologic characteristics determining management outcomes.The Journal of clinical endocrinology and metabolism · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. The Future of Somatostatin Receptor Ligands in Acromegaly.The Journal of clinical endocrinology and metabolism · 2022
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Potential markers of disease behavior in acromegaly and gigantism.Expert review of endocrinology & metabolism · 2020
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Wenjuan LiuDivision of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, China; Institute of Endocrinology and Diabetology, Fudan University, Shanghai 200040, China.
Lina XieDepartment of Endocrinology, Kunshan Rehabilitation Hospital, Suzhou, Jiangsu 215314, China.
Min HeDivision of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, China; Institute of Endocrinology and Diabetology, Fudan University, Shanghai 200040, China.
Ming ShenDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China; Shanghai Pituitary Tumor Center, Shanghai 200040, China.
Jingjing ZhuDepartment of Pathology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Yeping YangDivision of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, China; Institute of Endocrinology and Diabetology, Fudan University, Shanghai 200040, China.
Meng WangDivision of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, China; Institute of Endocrinology and Diabetology, Fudan University, Shanghai 200040, China.
Ji HuDepartment of Endocrinology, The Second Affiliated Hospital, Soochow University, Suzhou, Jiangsu 215004, China.
Hongying YeDivision of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, China; Shanghai Pituitary Tumor Center, Shanghai 200040, China.
Yiming LiDivision of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, China; Institute of Endocrinology and Diabetology, Fudan University, Shanghai 200040, China; Shanghai Pituitary Tumor Center, Shanghai 200040, China.
Yao ZhaoDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China; Shanghai Pituitary Tumor Center, Shanghai 200040, China.
Zhaoyun ZhangDivision of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, China; Institute of Endocrinology and Diabetology, Fudan University, Shanghai 200040, China; Shanghai Pituitary Tumor Center, Shanghai 200040, China.ORCID 0000-0001-5366-1353
Fudan University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expression of somatostatin receptor subtypes (SSTRs) in pituitary growth hormone- (GH-) secreting adenomas may predict the response to somatostatin analogues (SSA). Our aim was to evaluate the value of the immunohistochemical (IHC) scores of 2 subtypes, SSTR2 and SSTR5, in predicting the short-term efficacy of SSA therapy in patients with active acromegaly. Ninety-three newly diagnosed acromegalic patients were included in our study. These patients were categorized into either a SSA-pretreated group (SA,

Identifiers

PMID28396686
PMCPMC5370518
OpenAlexW2596120866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.